The NIH has awarded MIMETAS and the University of Pittsburgh a prestigious SBIR grant to develop a Liver-on-a-Chip platform for high throughput discovery and development. Accurate prediction of hepatotoxicity is a major problem in the development of new drugs leading to high development costs.  Animal hepatotoxicity testing is expensive, unsuited to high throughput and overall has unreliable concordance with human hepatotoxicity. MIMETAS scientists have teamed up with the University of Pittsburgh Drug Discovery Institute led by D. Lansing Taylor, Ph.D. to develop a liver-on-a-chip platform of unprecedented throughput, predictivity and usability. “We’re extremely happy to be working with Lans and his team on this project”, says Dr. Anthony Saleh of MIMETAS. “Prof. Taylor is a frontrunner in developing in vitro liver cultures and has vast experience with microfluidic techniques." “We were extremely impressed when we learned about the MIMETAS OrganoPlate platform”, commented Prof. Taylor. “It enables High Throughput, 3D co-culture with a vascular and hepatic compartments, as well as ease of handling. There is really no equivalent in the Organ-on-a-Chip space”.